Stock DNA
Pharmaceuticals & Biotechnology
SEK 8,199 Million (Small Cap)
41.00
NA
0.00%
-0.06
14.65%
5.86
Revenue and Profits:
Net Sales:
522 Million
(Quarterly Results - Jun 2025)
Net Profit:
54 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
48.15%
0%
48.15%
6 Months
-7.53%
0%
-7.53%
1 Year
-3.05%
0%
-3.05%
2 Years
77.05%
0%
77.05%
3 Years
196.38%
0%
196.38%
4 Years
150.58%
0%
150.58%
5 Years
257.14%
0%
257.14%
MedCap AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.96%
EBIT Growth (5y)
29.85%
EBIT to Interest (avg)
10.65
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.16
Sales to Capital Employed (avg)
1.30
Tax Ratio
20.23%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
19.53%
ROE (avg)
14.67%
Valuation key factors
Factor
Value
P/E Ratio
41
Industry P/E
Price to Book Value
6.21
EV to EBIT
32.36
EV to EBITDA
21.60
EV to Capital Employed
7.31
EV to Sales
4.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
22.60%
ROE (Latest)
15.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
521.70
457.70
13.98%
Operating Profit (PBDIT) excl Other Income
113.00
93.50
20.86%
Interest
6.90
5.80
18.97%
Exceptional Items
-4.00
0.00
Consolidate Net Profit
53.70
57.10
-5.95%
Operating Profit Margin (Excl OI)
151.20%
144.00%
0.72%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 13.98% vs 18.54% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -5.95% vs 22.01% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,806.70
1,587.40
13.82%
Operating Profit (PBDIT) excl Other Income
345.90
311.10
11.19%
Interest
18.50
15.60
18.59%
Exceptional Items
21.10
0.80
2,537.50%
Consolidate Net Profit
209.20
172.50
21.28%
Operating Profit Margin (Excl OI)
135.30%
139.60%
-0.43%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 13.82% vs 42.84% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 21.28% vs 46.19% in Dec 2023
About MedCap AB 
MedCap AB
Pharmaceuticals & Biotechnology
MedCap AB (publ) is a Sweden-based private equity company engaged in investments in and development of companies active primarily within the medical equipment sector. The Company reports four segments: Abilia, Unimedic, Quickels and Inpac. The Company’s portfolio includes such companies as Abilia AB, which is engaged in the development and marketing of aids within the fields of communication, cognition, noise and environmental control; Unimedic AB, engaged in contract manufacturing of liquid pharmaceuticals; Quickels Systems AB, which is engaged in the development and marketing of intensive medical care equipment, such as care bags and electrocardiogram (ECG) equipment; AirContainer Package System AB that offers a wide range of packaging solutions for the pharmaceutical industry, and Dunmedic AB, which offers medical products, medicines and food supplements.
Company Coordinates 
Company Details
Sundbybergsvagen 1 , SOLNA None : 171 73
Registrar Details






